Novo Nordisk Aims for U.S. Approval for Tresiba

Novo Nordisk Aims for U.S. Approval for Tresiba Play

Jan. 31 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk A/S stuck to its target of getting U.S. approval for the diabetes treatment Tresiba in the first half as it’s counting on the product to reach higher 2013 forecasts. She speaks on Bloomberg Television's "The Pulse."

  • On Air Now

    Bloomberg West Watch Now

  • Next

    PAID PROGRAMMING

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus